Evaluation of Bivalirudin in Percutaneous Coronary Intervention
Abstract
The aim of this study was to analyze the appropriateness of bivalirudin utilization indicated for percutaneous coronary interventions (PCI). A total of 218 patients who were admitted to University of Missouri Health Care that underwent a PCI were included in this retrospective study. Analysis was conducted for appropriate utilization of bivalirudin in patients with a history of heparin induced thrombocytopenia (HIT) over unfractionalized heparin. Bivalirudin use was found to be inappropriate in 170 of the 218 patients evaluated (78[percent]). By using, none experienced minimal bleeding, 15 experienced minor bleeding, three experienced major bleeding per the thrombolysis in myocardial infarction (TIMI) bleeding criteria, and none died as a result of bleeding complications.
Part of
Citation
Am J Hosp Med 2020 Oct;4(4):2020.19 https://doi.org/10.24150/ajhm/2020.019
Rights
OpenAccess.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.